IASLC关于肺神经内分泌肿瘤分类的更新
IASLC多学科专家组基于2021年WHO胸部肿瘤分类以来的新进展,提出肺类癌/神经内分泌肿瘤(NET)的新分类框架,要点包括推广NET命名、纳入Ki-67为诊断标准、正式认可类癌/NET G3概念,以助精准分型和治疗策略制定。
要点
- 新框架推广NET命名,同时保留类癌作为主要诊断术语
- Ki-67被纳入肺NET诊断标准
- 正式认可类癌/NET G3为罕见亚群,增殖活性增高但分子特征更接近肺NET
核心结论
- IASLC专家组提出肺类癌/NET新分类框架,以助精准肿瘤分型和治疗策略制定。
研究设计与样本
- IASLC多学科专家小组基于对当前肺NEN领域的综合综述进行审议,形成本立场文件。
主要发现
- 新分类框架继续从传统类癌术语转向更广泛采用NET命名,同时保留类癌作为主要诊断术语。
- Ki-67被纳入作为诊断标准,与其他器官NET分类实践保持一致。
- 正式认可类癌/NET G3概念,该亚群增殖活性增高但分子特征更接近肺NET而非高级别神经内分泌癌。
关键数值与推荐
- Ki-67被纳入作为肺NET诊断标准。
- 提出类癌/NET G3为罕见亚群,以增殖活性增高和分子特征更接近肺NET为特征。
临床怎么用
- 新分类框架有助于准确进行肿瘤分类并指导治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the publication of the 2021 WHO classification of thoracic tumors, our knowledge of pulmonary neuroendocrine neoplasms (NENs) has expanded significantly, particularly through the elucidation of molecular pathways and proposals to refine histopathologic classification. This expanded knowledge across all aspects of pulmonary NENs holds promise for more precise stratification of neuroendocrine tumors (NETs) and the potential development of novel, subtype-specific therapeutic strategies for all NENs. Based on our comprehensive review of the current pulmonary NEN landscape, our multidisciplinary expert panel has deliberated on the modification and updating of the 2021 classification, resulting in the proposal of a new pulmonary carcinoid/NET classification presented in this position paper, which incorporates the following three major points: (1) The proposed framework continues the shift from the traditional carcinoid terminology toward broader adoption of the "NET" nomenclature as found in other organ systems while retaining the term "carcinoid" as the primary diagnostic term to ensure clear communication with thoracic clinical providers. (2) Ki-67 has been incorporated as a diagnostic criterion, aligning with practices in other NET classifications. (3) There is formal recognition of the concept of "carcinoid/NET G3," a rare subset of lung carcinoids characterized by increased proliferative activity but with molecular features more aligned with pulmonary NETs than with high-grade neuroendocrine carcinomas. This position paper on the current knowledge of pulmonary NENs, including the proposed carcinoid/NET classification, will aid in accurate tumor categorization and guide treatment strategies.
引用
- Beasley MB, Yatabe Y, Papotti M, et al. IASLC Update on Classification of Pulmonary Neuroendocrine Neoplasms. J Thorac Oncol. 2026. PMID: 42251892. doi:10.1016/j.jtho.2026.103977
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。